๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Neuroendocrine Carcinoma Metastatic

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Whittier Daiichi Sankyo ยท Tests: Ifinatamab deruxtecan Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade NCT07130032Phase 21 site๐Ÿ“ Saint Petersburg EuroCityClinic LLC ยท Tests: reICB regimen (NSCLC), reICB regimen (melanoma) A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites๐Ÿ“ Aurora๐Ÿ“ Lake Mary๐Ÿ“ Lebanon 7 Hills Pharma, LLC ยท Tests: Alintegimod, Ipilimumab, Nivolumab A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230Phase 23 sites๐Ÿ“ Bordeaux๐Ÿ“ Nice๐Ÿ“ Villejuif Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Tarlatamab EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EBNK-001 + IL-15 + Pembrolizumab Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells NCT05691465Phase 213 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomogrโ€ฆ Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung NCT05058651Phase 2, Phase 3265 sites๐Ÿ“ Anchorage๐Ÿ“ Phoenix๐Ÿ“ Phoenix National Cancer Institute (NCI) ยท Tests: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography TIL Therapy in cSCC and MCC NCT07288073Phase 21 site๐Ÿ“ Boston Karam Khaddour, MD, MS ยท Tests: LN-145, Cyclophosphamide, Fludarabine, Interleukin-2 FTT PET/CT in Pancreatic Neuroendocrine Tumors NCT07114939Phase 11 site๐Ÿ“ Philadelphia Abramson Cancer Center at Penn Medicine ยท Tests: [18F]FluorThanatrace GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites๐Ÿ“ Goyang-si๐Ÿ“ Seoul๐Ÿ“ Seoul GeneMedicine Co., Ltd. ยท Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site๐Ÿ“ Adelaide SAPU NANO (US) LLC ยท Tests: Sapu003, Exemestane 25 MG Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer NCT05522660Phase 315 sites๐Ÿ“ Naples๐Ÿ“ Padova๐Ÿ“ Perugia ETOP IBCSG Partners Foundation ยท Tests: Stereotactic radiosurgery, Immune checkpoint inhibitor Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites๐Ÿ“ Scottsdale๐Ÿ“ Bethesda๐Ÿ“ Columbus Novartis Pharmaceuticals ยท Tests: dabrafenib, trametinib MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites๐Ÿ“ Tampa๐Ÿ“ Durham Memgen, Inc. ยท Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel A Study of CRD3874-SI in People With Solid Tumors NCT06021626Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: CRD3874 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer NCT05896839Phase 1, Phase 226 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites๐Ÿ“ Duarte๐Ÿ“ Glendale๐Ÿ“ La Jolla Turning Point Therapeutics, Inc. ยท Tests: Oral repotrectinib (TPX-0005) Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) NCT07179783Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Second Hospital ยท Tests: Sacituzumab Tirumotecan, Tagitanlimab Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Stanford Anusha Kalbasi ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site๐Ÿ“ Shanghai Hefei TG ImmunoPharma Co., Ltd. ยท Tests: TGI-5 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382Phase 2582 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test Genomic Investigation of Unusual Responders NCT03740503n/a1 site๐Ÿ“ Toronto University Health Network, Toronto Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases NCT02185443Phase 21 site๐Ÿ“ Sรฃo Paulo University of Sao Paulo ยท Tests: SBRT [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers NCT06479811Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) NCT06940440Phase 12 sites๐Ÿ“ Tampa๐Ÿ“ Madison TuHURA Biosciences, Inc. ยท Tests: IFx-Hu2.0, Pembrolizumab A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer NCT05361174Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ Miami๐Ÿ“ Orlando Iovance Biotherapeutics, Inc. ยท Tests: IOV-4001 A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Lake Success MacroGenics ยท Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy